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Lessons learned: new insights on the role of 
cytokines in COVID-19
In the midst of resurging COVID-19 cases, the second NIH/FDA virtual COVID-19 and Cytokines symposium was held 
on 1 December 2020, focusing on longitudinal studies of COVID-19 immunity, including long-term consequences, 
potential associations with autoimmunity and the multisystem inflammatory syndrome in children (MIS-C).
A central and ongoing quest in COVID-19 research is to establish why and how SARS-CoV-2 
elicits heterogeneity in disease severity 
and immunopathology among infected 
individuals. Hence, much effort has been 
exerted to understand the cellular basis of 
SARS-CoV-2-induced immune responses, 
with the aim of identifying new biomarkers 
and prognostic tools and developing new 
therapeutic options. Cytokines emerged 
early as critical parameters in COVID-19 
disease progression, and understanding 
the qualitative, quantitative and temporal 
differences in cytokine expression is 
considered critical for the conquest  
of COVID-19.
As the late-2020 fall surge brought the 
third phase of the COVID-19 pandemic, 
with record numbers of new cases and 
deaths, the NIH/FDA Immunology, 
COVID-19, and Cytokine Interest Groups 
hosted the second NIH/FDA virtual 
COVID-19 and Cytokines symposium, 
bringing together experts in these areas 
to present the most up-to-date data 
and to provide a forum for discussion, 
which focused on recent immunological 
characterization of the disease and its 
consequences, including MIS-C.
Opening with a summary of the current 
challenges and achievements in fighting 
SARS-CoV-2, Anthony Fauci (NIAID/NIH)  
and Janet Woodcock (CDER/FDA) 
presented a road map for extending these 
efforts, as our understanding of the disease 
and tools for managing COVID-19 are 
evolving1. Fauci reflected on parallels with 
the human immunodeficiency virus (HIV) 
epidemic in the 1980s, which revealed gaps 
in our knowledge but also led to many 
outstanding basic and clinical discoveries. 
Similarly, COVID-19 is an enormous 
public health problem that challenges 
scientists and clinicians to rapidly advance 
our understanding of the immune system 
and its impact on human disease. Fauci 
further emphasized the importance of 
delineating the role of cytokines in COVID-
19 pathogenesis and resolution and the 
effects of antiviral and immunomodulatory 
treatment strategies, as well as vaccines, 
on immune responses. In turn, Woodcock 
pointed out that therapeutic interventions 
serve as a learning tool and can provide new 
insights into the pathogenesis of the disease. 
However, the lack of markers defining 
different stages of the disease has impeded 
our understanding of the proper timing for 
treatment regimens, with some therapies 
resulting in negative effects when given too 
late or too early in the disease course. The 
work presented in this symposium outlined 
efforts to address these issues.
Cellular origins of cytokines in 
COVID-19
Adrian Hayday (Crick Institute and King’s 
College) led the meeting by presenting 
the results of a comprehensive analysis 
of 63 patients with COVID-19 who were 
segregated into three groups on the basis of 
their disease severity. Patients were listed 
as ‘low’ when mildly symptomatic (WHO 
scores 1–2), ‘moderate’ when little or no 
supplemental oxygen was required (WHO 
scores 3–4) and ‘severe’ when they showed 
any of the following indications: high-flow 
oxygen requirement, mechanical ventilation, 
multi-organ support or death (WHO scores 
5–8). At the same time, 55 healthy adult 
volunteers, of whom 23 had previously 
experienced SARS-CoV-2 infection 
without hospitalization, served as healthy 
controls. Approximately 600 data points 
were collected from an initial and then two 
subsequent blood samplings, and these 
data included complete serology, immune 
cell analysis and, importantly, cytokine 
expression (data are publicly available at 
COVIDIP). Principal component analyses 
of the datasets showed a clear segregation 
of COVID-19 samples from control 
samples, but no segregation of seropositive 
and seronegative healthy controls2. Thus, 
COVID-19 imposes a distinct immune 
phenotype. A striking feature of immune 
responses associated with severe COVID-19 
turned out to be the loss of plasmacytoid 
dendritic cells and basophils, which is 
accompanied by extreme T cell cytopenia, 
which mainly manifests as CD8+ T and 
γδT cell depletion, even though T cells 
are not targeted by SARS-CoV-2. Hayday 
reminded us that isolated parameters rarely 
provide immunological answers to viral 
infections and that, in fact, the correlations 
between the parameters provide more 
insight about a given pathology. As such, it 
was interesting that the expression of a triad 
of cytokines, comprising interleukin (IL)-6,  
IL-10 and interferon (IFN)-γ-induced 
protein 10 (IP-10), is closely correlated  
with disease progression. IP-10 (CXCL10)  
is of particular interest because its 
expression pattern in patients with  
COVID-19 is distinct from that observed 
with conventional viral infections. While 
IP-10 is rapidly but transiently induced 
in common cold viral infections, IP-10 
concentrations frequently remain elevated 
throughout the COVID-19 response. 
Moreover, a decline in the level of serum 
IFN-γ, a strong inducer of IP-10 expression, 
did not affect IP-10 concentrations. These 
findings suggest that IP-10 expression in 
COVID-19 is maintained independently of 
IFN-γ, albeit in a virus-dependent manner. 
This distinct cytokine profile was confirmed 
in an expanded study with 305 samples, 
whereby the rise in cytokine production 
correlated prognostically with deterioration 
of patient health status. Notably, the 
expression of IP-10, together with IL-6  
and IL-10, was found to persist with 
COVID-19 for over 72 hours after 
admission. Elevated IP-10 was previously 
reported for SARS-CoV and Middle 
East respiratory syndrome coronavirus 
(MERS-CoV) infections, so these features 
may represent an immune signature of 
severe coronavirus infection.
Identifying the distinct cytokine profile 
and immune signature of COVID-19 
has practical implications, as it can be 
prognostic of clinical deterioration, such 
as requiring intubation or mortality. 
This led to the important question of 
whether such distinct immune profiles 
are only correlated with symptomatic 
SARS-CoV-2 infection or whether they 
are also associated with asymptomatic 
individuals with SARS-CoV-2. To address 
this question, Nina Le Bert (Duke-NUS 
Medical School) studied a cohort of patients 
in Singapore. Here, she asked whether the 
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T cell immune responses in symptomatic 
versus asymptomatic COVID-19 differ 
and whether disease severity would vary 
depending on the quality of the immune 
response. Importantly, COVID-19 cases 
in Singapore represented a unique chance 
to assess an understudied population, as 
many patients are migrant workers, who 
mostly reside in crowded dormitories. 
Among the initial 541 recruits, 478 patients 
underwent the initial assessment as well 
as 2-week and 6-week follow-up exams. 
This cohort was then divided on the basis 
of COVID-19 symptoms: 44 individuals 
were symptomatic, and the rest of the 
individuals who tested positive (90.8%) were 
asymptomatic. One of the first questions 
was whether asymptomatic patients would 
also mount productive immune responses to 
SARS-CoV-2. The answer was a resounding 
yes: anti-nucleoprotein IgG and neutralizing 
antibody titers were comparable to those of 
symptomatic patients. Titers also increased 
with time (measured at 2 and 6 weeks after 
the initial assessment), indicating a robust 
humoral immune response regardless of 
symptoms. To examine whether there 
would be qualitative differences in the T cell 
responses between the two groups, Le Bert 
and colleagues utilized a pool of overlapping 
peptides derived from the SARS-CoV-2 
membrane (M), nucleoprotein (NP) and 
spike (S) proteins and challenged T cells 
from both symptomatic and asymptomatic 
individuals. Both the strength and antigen 
specificity of T cell responses showed 
no major differences, indicating that the 
magnitude of B or T cell reactivity did not 
correlate with disease outcome. Next, whole 
blood cells were stimulated with pools of 
15-mer peptides from structural proteins of 
SARS-CoV-2 and were assessed for cytokine 
expression. The results demonstrated 
that both symptomatic and asymptomatic 
patients mounted strong cytokine responses 
but that they segregated into distinct 
clusters, wherein asymptomatic individuals 
showed high expression of IL-2 and IFN-γ 
while symptomatic individuals showed low 
expression of IL-2 and IFN-γ. Collectively, 
Le Bert’s data, as well as data from  
Hayday, indicated that a combination of 
parameters can segregate patients and  
reflect their condition.
Another important but poorly 
understood parameter is the contribution 
of host factors to disease development 
and progression. In this regard, Raphaela 
Goldbach-Mansky (NIAID, NIH) 
summarized her efforts to identify 
the distinct immunological features of 
SARS-CoV-2 infection in the context of the 
host inflammatory response in patients with 
severe disease. Whether the inflammatory 
responses in COVID-19 replicate those 
in autoinflammatory diseases or whether 
there are unique features in SARS-CoV-2 
infection is not clear. In a joint effort 
with Luigi Notarangelo and Helen Su 
(both from NIAID), Goldbach-Mansky 
analyzed a cohort of critically ill patients 
from Northern Italy, focusing on changes 
seen in inflammasomopathies and 
interferonopathies. While autoinflammatory 
diseases such as the macrophage 
activation syndrome (MAS) or secondary 
hemophagocytic lymphohistocytosis 
(HLH) trigger ultra-high concentrations 
of IL-18, COVID-19 elicited only modest 
concentrations of this cytokine (Fig. 1). 
Also, COVID-19 was rarely associated with 
thrombocytopenia or hypertriglyceridemia, 
which is distinct from what is observed 
with MAS. Instead, patients with COVID-
19 displayed features of strongly activated 
cytokine/chemokine secretion pathways 
that are associated with NF-κB activation 
and type II IFN expression. Conversely, the 
antiviral pathway in COVID-19 appears 
to be paralyzed, as demonstrated by weak 
type I IFN responses. Thus, the loss of the 
type I IFN response can be considered an 
immune signature of COVID-19. In fact, 
genetic variants affecting type I-IFNs3 or the 
surprising presence of neutralizing type I 
IFN autoantibodies4 correlate with disease 
severity in some patients with COVID-19.
Along these lines, Alessandro Sette 
(La Jolla Institute for Immunology) asked 
whether there is pre-existing immunity 
to SARS-CoV-2 in unexposed individuals 
and, if so, how this could affect disease 
progression. To understand the adaptive 
immune response to SARS-CoV-2, Sette’s 
group ventured to map the T cell epitopes in 
convalescent patients with COVID-19 and 
healthy unexposed controls5. Surprisingly, 
SARS-CoV-2-reactive CD4+ T cells were 
already present at significant frequencies 
(~40–60%) in unexposed (obtained 
before the emergence of SARS-CoV-2) 
individuals. Epitope mapping further 
revealed that these T cells (1) were mostly 
reactive to non-spike proteins, (2) displayed 
much greater responsiveness to peptides 
from the homologous regions of the 
common cold coronaviruses (CCC) than 
to SARS-CoV-2 peptides and (3) were 
mostly memory CD4+ T cells. Thus, these 
results strongly suggested that there is 
pre-existing immunity to SARS-CoV-2 in 
healthy donors, which was acquired from 
past infections with CCC. Whether such 
cross-reactive antiviral immunity provides 
protection against COVID-19 remains 
to be examined. However, it is likely that 
pre-existing T cell immunity would only 




















Fig. 1 | the family of disease states that fall under the umbrella term ‘cytokine storm’. The disease 
phenotype of COVID-19 resembles that of other pathological syndromes that are driven by uncontrolled 
immune system activation and cause cytokine storm. The consequent inflammation can lead to 
tissue and organ damage. COVID-19 has overlap with features of acute respiratory distress syndrome 
(ArDS) and post-viral syndromes. MIS-C has less lung involvement (ArDS) and more features of 
Kawasaki disease. Assoc., association; CrS, cytokine release syndrome; EBV, Epstein–Barr virus; HLH, 
hemophagocytic lymphohistiocytosis; Malig., malignancy; MAS, macrophage activation syndrome; SJIA, 
systemic juvenile idiopathic arthritis.
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prevent the infection itself. In support of 
this hypothesis, T cell epitope mapping in 
convalescent individuals revealed that the 
repertoire significantly differed from that 
in unexposed individuals. In-depth analysis 
of T cell epitopes from 100 convalescent 
individuals further identified a total of 280 
major histocompatibility complex (MHC) 
class II epitopes. These important data 
revealed that the receptor-binding domain of 
SARS-CoV-2 spike protein is a weak CD4+ 
T cell antigenic determinant and that 15–20 
different epitopes are recognized by each 
individual. For CD8+ T cells, a total of 523 
MHC class I epitopes were identified, which 
unveiled an interesting dichotomy between 
the frequency and reactivity of the human 
leukocyte antigen haplotype. As such, less 
frequent HLA-A*0101-associated epitopes 
showed a more vigorous response than 
HLA-A*2601- and HLA-A*6801-associated 
epitopes. Altogether, these results 
documented a COVID-19-specific signature 
in the T cell immune response that is 
distinct from the response to CCC, and 
epitope mapping further showed that HLA 
binding is the main determinant of the 
immunogenicity of SARS-CoV-2.
multisystem inflammatory syndrome 
in children
Despite initial optimism that children were 
spared from the worst effects of COVID-19 
(ref. 6), it soon became clear that children 
could not only develop severe COVID-19 
but also a rare secondary inflammatory 
syndrome, now known as MIS-C. However, 
the molecular basis of MIS-C and its 
pathogenesis remain poorly understood. 
Randy Cron (University of Alabama at 
Birmingham) started the second session by 
providing a comprehensive overview of the 
history, clinical presentation and treatment 
of this syndrome (Fig. 2). MIS-C was first 
identified when the pandemic moved to 
Europe and reports from Northern Italy7 
and then the UK8 noted an approximately 
30-fold increase in what was thought to be 
Kawasaki disease (KD), an inflammatory 
syndrome in children associated with fever, 
rash, mucocutaneous inflammation and 
vasculitis, particularly of cardiac arteries. 
However, these patients were generally 
more severely ill and had positive serology 
for SARS-CoV-2, indicative of previous 
infection or exposure and thus suggesting a 
distinct entity. MIS-C has many overlapping 
features with KD and toxic shock syndrome, 
but patients are often older than those with 
KD, which usually occurs in children under 
the age of five. A similar post-COVID-19 
inflammatory syndrome is also observed 
in young adults but with more evidence 
of carditis, including cardiac dysfunction, 
shock and neurological involvement. 
Notably, patients with MIS-C have more 
pronounced lymphopenia, anemia and 
thrombocytopenia as compared to patients 
with KD. In addition to high C-reactive 
protein (CRP) levels, troponins and 
N-terminal pro-B-type natriuretic peptide 
were specifically elevated, indicative of 
cardiac involvement8. As the pandemic 
spread to the US, reports of a similar disease 
in New York and other states9,10 noted high 
frequencies of gastrointestinal (GI) and 
hematological features. The peak of MIS-C 
in affected geographical regions generally 
occurs a month or more after the peak 
incidence of COVID-19 infections.
Cron proposed that KD is probably a 
syndrome with multiple triggers (including 
a previous infection with another 
coronavirus) and proposed that MIS-C and 
severe COVID-19 infection be included 
under the umbrella of similar cytokine 
storm syndromes (Fig. 1)11. He described 
studies on the immunological effects of 
MIS-C12,13, which included lymphopenia, 
thrombocytopenia and elevated serum 
IFN-γ, IL-1β, IL-6, IL-10 and IL-17 
concentrations, although not to the same 
extent as in the more severe cytokine storm 
syndromes. Elevated concentrations of 
IL-10 correlated with a lower viral load13, 
and its presence together with elevated 
concentrations of tumor necrosis factor 
(TNF) was the best marker to distinguish 
MIS-C from severe COVID-19. Notably, 
unlike severe COVID-19, MIS-C is not 
associated with pre-existing comorbidities, 
with the occasional exception of asthma. 
Cron outlined treatment options, which 
included immunomodulatory agents 
such as intravenous immunoglobulin 
infusions, as used for KD, glucocorticoids, 
anakinra (IL-1 receptor antagonist) and 
infliximab (a monoclonal antibody to 
TNF); antimicrobials, including remdesivir 
and broad-spectrum antibiotics (as 
some patients’ clinical pictures resemble 
bacterially induced toxic shock syndrome); 
and, in severe cases, mechanical ventilation, 
pressor support and anticoagulants8,9,14,15. 
Updated treatment guidelines were 
published recently by the American College 
of Rheumatology16.
To investigate MIS-C from a systems 
biology perspective, similar to studying 
COVID-19 in adults, Dusan Bogunovic 
(Icahn School of Medicine at Mount Sinai) 
described analyses of about 40 patients 
treated at Mount Sinai in New York who 
presented with the symptoms of MIS-C and 
who met diagnostic criteria16. Treatment 
with an IL-6R blocker and intravenous 
immunoglobulin led to discharge, usually 
within 5 days, with universally favorable 
outcomes. To provide molecular insight 
into the disease, they combined serology, 
cytokine profiling, high-throughput 
85-parameter immunophenotyping and 
autoantibody analysis for nine of these 
patients17. MIS-C SARS-CoV-2 antibody 
responses resembled those seen in 
convalescence, including effective virus 
neutralization in vitro, but with lower IgM 
and higher IgA concentrations. Multiplex 
cytokine array data revealed a unique MIS-C 
inflammatory cytokine signature not seen 
in healthy controls or patients with COVID-
19, which included the expression of 
chemokines (CXCL1, CXCL6 and CXCL11, 
as well as CCL3 and CCL19) and cytokines 
(including IL-6 and IL-17A, as noted by 
Cron) involved in myeloid cell chemotaxis 
and inflammation. In parallel, mass 
cytometry immunophenotyping suggested 
immune cell activation and egress of natural 
killer (NK) and myeloid cells to peripheral 
organs. Autoantibody analysis indicated the 
presence of both autoantibodies targeting 
organs central to MIS-C pathology, 
including the GI tract, immune cells 
and cardiac and epithelial tissue, and 
some previously described autoantigens. 
Interestingly, pathways involved in the 
sensory detection of smell were also targeted 
by autoantibodies. Using cellular indexing of 
transcriptomes and epitopes by sequencing 
(CITE–seq) to simultaneously detect surface 
antigens and perform single-cell RNA 
sequencing (scRNA-seq), Bogunovic and 
his group found increased expression of 
genes involved in lymphocyte activation and 
cytotoxicity of NK and CD8+ T cells. These 
findings were particularly pronounced in 
a subset of patients who showed increased 
phosphorylation of the signaling molecule 
STAT3 across cell types.
To further address the molecular 
mechanisms of MIS-C immunopathology, 
Carrie Lucas (Yale School of Medicine) 
focused on two potential causes of 
post-COVID-19 MIS-C: (1) a rare second 
hit with a pathogen within a certain window 
of time after SARS-CoV-2 infection and (2) 
a unique immune response to SARS-CoV-2 
that triggers a transient reactivity against the 
self. Lucas presented her team’s recent work 
on a cohort of 15 patients who developed 
MIS-C approximately 1 month after a peak 
of COVID-19, whom they stratified into 
two groups according to disease severity 
(patients with severe disease were those 
requiring ventilatory support or pressors) 
(Fig. 2)18. She described CITE–seq results, 
including T cell antigen receptor (TCR) and 
B cell antigen receptor (BCR) repertoire 
analyses, for peripheral blood mononuclear 
cells from seven patients with MIS-C, as 
well as from pediatric and adult patients 
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with COVID-19 and controls. Evaluation 
of transcriptional responses revealed that 
antirespiratory virus and antibacterial 
response signatures were low in patients 
with MIS-C, confirming that SARS-CoV-2 
infection was cleared, with no evidence 
of secondary infection. Moreover, no 
reads were present for Epstein–Barr 
virus or cytomegalovirus. In parallel, 
serum proteomics confirmed elevated 
proinflammatory cytokines and chemokines 
involved in myeloid cell infiltration into 
the tissues, similar to the findings from 
Bogunovic. Looking for the drivers of 
this hyperinflammatory phenotype, they 
analyzed gene expression in different cell 
types and found that the expression of genes 
encoding S100A alarmins was elevated 
(similar to results in a recent report on 
COVID-19 by Guo et al.19) and class II HLA 
and CD86 were downregulated in myeloid 
cells. Again, in NK cells and CD8+ T cells, 
cytotoxicity genes (encoding perforin 
and granzymes A and H) and IL-32 were 
elevated (Fig. 2). Lucas also noted increased 
numbers of plasmablasts in patients with 
MIS-C, which were enriched for IgG1 
or IgG3 isotypes and correlated with 
proliferating CD4+ T cells with a B helper 
gene profile. Patients with severe MIS-C 
exhibited less TCR and BCR diversity, 
elevated numbers of plasmablasts and 
greater somatic hypermutation as compared 
to the moderate disease group. The patients 
with severe disease also exhibited elevated 
concentrations of serum soluble E-selectin, 
also seen in KD, suggesting endothelial 
damage; functional experiments provided 
evidence for serum IgG antibodies 
recognizing cultured endothelial cells.
Together with the work of Bogunovic, 
these studies provide insight into 
immunological signatures of MIS-C, 
which, along with functional studies and a 
potential mouse model, may help predict, 
prevent and treat MIS-C post-SARS-CoV-2 
infection in children. Nonetheless, many 
questions remain, including whether 
there is a specific trigger for MIS-C and 
whether there are contributions from the 
gut commensal microbiota or pathogens, 
associations with food, or oral routes of 
transmission, given the involvement of 
the GI tract. Furthermore, although there 
was no evidence of secondary respiratory 
infection as a MIS-C trigger, tissue-specific 
































































Fig. 2 | Immunopathology associated with mIS-C post-SarS-CoV-2. MIS-C is characterized by fever and cardiovascular, GI tract, neurological, respiratory 
and mucocutaneous inflammation. Immunological features include activation of both innate and adaptive responses, including elevated expression of genes 
encoding S100 alarmins and increased concentrations of acute phase proteins (CrP, ferritin and D-dimers) as well as IL-6, IL-1β and CXCL10, indicative of 
systemic inflammation. Activation of NK and CD8+ T cell cytotoxicity probably contributes to inflammation, as well as increased numbers of proliferating 
plasmablasts, which may produce autoreactive IgGs. Endothelial damage is evidenced by elevated concentrations of soluble E-selectin in the serum and 
cardiac damage by increased amounts of troponin and N-terminal pro-B-type natriuretic peptide (BNP). Figure adapted with permission from ref. 18, Cold 
Spring Harbor Laboratory; made in ©Biorender—biorender.com.
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from gut infections) or the involvement of 
superantigens, a topic that was addressed in 
the next talk, could not be ruled out.
autoimmunity and other long-term 
consequences of COVID-19
One of the most notable clinical outcomes 
of SARS-CoV-2 is the induction of 
autoimmune disease that persists long 
after the resolution of acute viral infection 
in a subpopulation of patients. This topic 
was the focus of the talks from Alessio 
Fasano (Massachusetts General Hospital), 
Virginia Pascual (Weill Cornell Medicine) 
and Leonard Calabrese (Cleveland Clinic), 
who presented different aspects of the 
intersection between COVID-19 and 
autoimmunity. Fasano opened the session 
by conveying data from several studies 
performed in Italy suggesting that the 
prevalence and severity of COVID-19 
in patients with autoimmune diseases 
(AIDs) is similar to those of the general 
population20. However, symptoms consistent 
with immune thrombocytopenic purpura 
(ITP), Miller Fisher syndrome, Guillain–
Barré Syndrome (GBS), anti-phospholipid 
syndromes (APLS) and MIS-C have 
been described in patients following 
SARS-CoV-2 infection, leading his group 
to focus on the molecular mechanisms 
that make the development of AIDs more 
likely in patients with COVID-19 patients. 
His talk centered on three principal 
hypotheses21 underlying the induction of 
autoimmunity by severe viral infection: 
molecular mimicry, viral and bacterial 
superantigens altering the T cell repertoire, 
and lymphocyte apoptosis followed by 
expansion of autoreactive lymphocytes. 
Regarding molecular mimicry, he remarked 
on multiple shared motifs between the 
spike protein and human chaperone 
proteins and hypothesized that altered 
processing and presentation of endogenous 
antigens could foster the recognition of 
self-antigens. He also hypothesized that the 
loss of tolerance associated with lymphocyte 
apoptosis during acute infection followed 
by a skewed expansion of the repertoire 
could be involved, leading eventually to 
autoimmunity, as proposed by Canas 
et al22. However, Fasano considered the 
strongest mechanistic trigger for the 
hyperinflammatory syndrome and AID 
induction to be viral superantigens within 
SARS-CoV-2, which induce non-specific 
activation and expansion of a distinct 
population of T cells with a skewed TCR 
repertoire, which leads to the expansion of 
plasmablasts23. In particular, the expansion 
of TCRBV11-2-bearing T cells appeared to 
correlate with elevated proinflammatory 
cytokines associated with cytokine storm 
in children with MIS-C24. Lastly, drawing 
from the parallels between MIS-C and 
KD, Fasano described a potential role for 
zonulin-dependent increased permeability 
of the intestinal epithelial barrier and 
proposed a provocative hypothesis wherein 
the viral infection results in intestinal 
dysbiosis (pertaining to altered gut 
microbiota composition and function), 
which then triggers MyD88-dependent 
zonulin release. Once released, zonulin 
binds to the proteinase-activated receptor 2, 
triggering a sequence of signaling  
events that ultimately cause disassembly  
of tight junctional complexes and  
increased GI mucosal permeability. This 
increased mucosal permeability permits 
viral or even bacterial antigens to be 
internalized and act as superantigens, 
thus triggering a cytokine storm and 
autoimmunity (Fig. 3).
The autoimmune component of 
COVID-19 was also explored by Pascual, 
who described multiple studies indicating 
parallels between COVID-19 and 
autoimmune disorders. After describing 
the clinical features shared by COVID-19 
and AIDs, she focused on mechanistic 
commonalities, particularly the central role 
of type I IFNs. Citing findings published 
by Casanova, Su and others regarding 
the increased severity of COVID-19 in 
patients with reduced IFN function due 
to inborn errors in type I IFN immunity 
or autoantibodies to type I IFNs3,4, she 
emphasized the critical role of type I IFN 
in controlling viral load. At the same 
time, she remarked that the pattern of 
IFN-inducible genes expressed following 
a viral infection is similar to that in 
systemic lupus erythematosus (SLE) and a 
number of monogenic interferonopathies 
described in children, as well as in subsets 
of patients with other AIDs such as 
Sjogren’s, dermatomyositis, thyroiditis and 
diabetes, suggesting that it may underlie 
some of the clinical features. Citing results 
from Goldbach-Mansky and Notarangelo 
that showed a 10-fold increase in type I 
IFNs as well as an association between 
CXCL10 and COVID-19 severity, Pascual 
remarked that, although the expression of 
interferon-inducible genes was lower in 
patients with COVID-19 than in children 
with interferonopathies or pediatric SLE, 
it was in line with that observed in adults 
with SLE25, leading her to emphasize the 
different type I IFN responses in pediatric 
and adult patients. In support of an 
autoimmune component for COVID-19, 
Pascual also remarked on the presence of 
antibodies to IFNs, coagulation factors, 
phospholipids and nucleic acids in patients 
with COVID-19, which are characteristic of 
several autoimmune disorders, signaling the 
need to evaluate the long-term persistence 
and potential sequelae of these antibodies 
in patients that survive COVID-19. 
Pascual, then focused on the emergence of 
autoreactive T and B cells, again drawing 
interesting parallels between the adaptive 
immune responses in patients with COVID-
19 and pediatric patients with SLE. She 
pointed to studies by Ignacio Sanz that 
showed a potential role for the extrafollicular 
activation of autoreactive B cells in patients 
with severe COVID-19, drawing parallels 
with SLE and underscoring a potential role 
for a subpopulation of memory B cells that 
lack follicular and conventional memory 
markers but express Toll-like receptor 7 
(TLR7) and antigen-presenting markers, 
also seen in the peripheral blood of patients 
with SLE26–28. She further proposed that the 
surge in these extrafollicular plasmablasts 
is possibly helped by extrafollicular 
proinflammatory T cells displaying 
exhaustion/hyperproliferative and cytotoxic 
markers, as recently described for severe 
COVID-19 (refs. 29,30). Interestingly, CD4+ 
T cells with similar characteristics that 
lack follicular markers are also reported in 
children with SLE, reinforcing the concept 
that the dysfunctional immune response 
in severe COVID-19 resembles that found 
in SLE. Pascual then proposed a model 
wherein virus-activated plasmacytoid 
dendritic cells (pDCs) produce type I IFN 
that primes CD4+ T cells to provide help 
to extrafollicular B cells in unconventional 
ways, as they do in SLE31. While the 
cellular source of type I IFN has not been 
confirmed, given the reported reduction 
in blood pDCs in patients with COVID-19 
(ref. 17) and SLE, she speculated that this 
could correspond to increased migration 
of pDCs to inflamed tissues32. Pascual’s talk 
stressed that mechanistic understanding 
of autoimmune diseases may help to 
decipher the pathogenicity of COVID-19 
and identify therapeutic targets. In turn, 
detailed longitudinal studies of patients with 
COVID-19 may shed light on pathogenic 
autoimmune mechanisms and the potential 
for immunomodulatory therapeutics to 
mitigate autoimmune diseases.
The theme of shared mechanisms 
between AIDs and COVID-19 was picked 
up by Leonard Calabrese, who closed the 
session by asking two questions: what can 
we learn about cytokines in COVID-19 by 
examining the outcomes for individuals with 
pre-existing autoimmune/autoinflammatory 
disorders who develop COVID-19, and what 
effects do the commonly used therapies 
for such autoimmune diseases, including 
immune-pathway-targeted biologics 
and non-biological disease-modifying 
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anti-rheumatic drugs (DMARDs), have on 
the clinical outcome of COVID-19?
He consulted three patient registries to 
attempt to answer these critical questions: 
the COVID-19 Global Rheumatology 
Alliance (GRA), consisting of the Global 
UCSF Registry (3,572 patients) and the 
European/EULAR registry (3,239 patients), 
representing the largest database; the 
Secure-IBD Database on COVID-19 (based 
at the University of North Carolina at Chapel 
Hill), a web-based voluntary reporting 
system in which health care providers 
report confirmed COVID-19 cases and 
patient outcomes along with medication 
exposure data; and the Psoriasis Registry for 
Outcomes, Therapy and epidemiology of 
COVID-19 infection (PsoProtect), containing 
557 cases (at the time of reporting).
Calabrese pointed out that these 
registries are imperfect for evaluating the 
effects of underlying disease per se, as each 
may impact COVID-19 prognosis, given 
the markedly disparate and heterogeneous 
diseases in these databases. However, 
the effect of baseline therapies and risk 
factors for severe disease or death were 
still critically analyzed despite important 
limitations regarding selection bias, low 
granularity, lack of control comparators 
and residual confounding factors in such 
registries. He repeatedly emphasized that 
such studies were important for hypothesis 
generation rather than for producing 
conclusive findings.
Initially reported at the American 
College of Rheumatology meeting in 
November 2020, data were also presented 
at this meeting that examined risk factors 
associated with death in the GRA database 
from a population of over 4,000 patients. 
Adjusting for multiple variables, the 
following were associated with an increased 
risk of death from COVID-19 (odds  
ratio > 1): no DMARDs, sulfasalazine, 
rituximab, and glucocorticoids at a dose 
of >10mg per day. While rituximab’s 
risk stems from the failure to generate 
humoral immunity (and possibly T cell 
immunity due to the lack of B cell antigen 
presentation), and glucocorticoids at the 
higher dose potently suppress antiviral 
responses, the mechanism by which the 
absence of DMARDs and sulfasalazine 
contribute to enhanced risk is less clear. The 
risk pertaining to glucocorticoids was also 
identified in the SECURE-IBD database, 
and a multivariate analysis (controlling 
for age, sex, disease type, disease activity, 
comorbidities, smoking, obesity, aspirin, 
and anti-TNF medication) revealed an 
odds ratio of 6.87 for patients on higher 
doses of steroids at the time of contracting 
COVID-19. Similar results were found in 
other IBD databases from Italy and the US. 
Nonetheless, the need to understand the 
context of glucocorticoid administration 
was emphasized; while dexamethasone was 
associated with poorer outcomes for patients 
treated with higher doses of glucocorticoids 
at the time of acquiring COVID-19 and 
for patients with mild to moderate disease 
(no oxygen required), it reduced deaths by 
one third for patients receiving invasive 
mechanical ventilation, and it is now the 
standard of care (RECOVERY trial).
Calabrese then discussed the significance 
of elevated inflammatory cytokines and the 
effects of their blockade on the outcome of 
COVID-19. He pointed to the importance 
of TNF concentrations and downstream 
IL-6 and IL-8 concentrations as directly 
correlated with poor outcomes, including 
hospitalization, transfer to an intensive care 
unit, mechanical ventilation and death33,34. 
He also emphasized the contribution  
of TNF to diverse phenomena affecting 
COVID-19, including neutrophil activation 
and the release of neutrophil extracellular 
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Fig. 3 | Hypothesis on the pathogenesis of multisystem inflammatory syndrome in children and in adults (mIS-a). (1) Under physiological circumstances, 
the homeostasis of the intestinal mucosa is maintained through tightly controlled antigen trafficking from the gut lumen into the lamina propria. (2) The 
presence of SArS-CoV-2 (either as viable or non-viable viruses) in the GI tract causes dysbiosis and upregulates the expression of zonulin, a molecule that 
controls paracellular permeability. (3) The zonulin-dependent increased gut permeability allows the paracellular passage of large, intact molecules, including 
SArS-CoV-2-derived spike proteins, into the lamina propria. (4) Spike proteins, acting as superantigens, trigger T cell proliferation and cytokine storm, with 
subsequent onsets of severe GI symptoms and systemic inflammation, which are typical of MIS-C and MIS-A. IVIG, intravenous immunoglobulin. SIgA, 
secretory immunoglobulin A.
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the loss of germinal centers and induction 
of extrafollicular B cell responses, as well as 
the generation of autoantibodies, including 
phospholipid antibodies33. In this context, 
he discussed analyses of the registries to 
determine the effects of TNF blockers on 
COVID-19. In both the GRA and PsoProtect 
databases, treatment with TNF inhibitors 
was associated with a favorable outcome, 
with an odds ratio of 0.4 in the in the GRA 
database (for hospitalization) and 0.60 in the 
PsoProtect database (for intensive care unit 
admission, need for mechanical ventilation, 
and death). However, in the SECRURE-IBD 
database, which employed a multivariate 
analysis, TNF inhibition was associated with 
a non-significant odds ratio of 0.9 for severe 
outcomes. It is critical to note, however, that 
the outcome was not worsened in patients 
on TNF inhibitors and that such treatment 
may potentially be beneficial.
The important topic of synergism 
between cytokines in contributing to the 
devastating hyperinflammation associated 
with severe COVID-19 and whether 
inhibition of multiple inflammatory 
cytokines would improve the outcome 
was discussed next. Citing work from 
murine models, Calabrese discussed data 
showing that TNF and IFN-γ can synergize 
in mediating PANoptosis (pyroptosis, 
apoptosis and necroptosis), associated with 
the induction and perpetuation of cytokine 
storm and cell death that is observed in both 
sepsis and COVID-19 animal models35. 
Moreover, treatment of murine cytokine 
storm models, including SARS-CoV-2 
infection, HLH and sepsis, with a 
combination of TNF and IFN-γ inhibitors 
markedly improved the outcome, suggesting 
that dual blockade as compared to single 
agents may improve outcomes in patients.
Blockade of IL-6 or IL-6R is known 
to improve the outcome in patients with 
cytokine release syndrome associated with 
CAR-T cell therapy. However, although 
serum IL-6 concentrations are correlated 
with severe outcomes in COVID-19, 
Calabrese noted that they are more similar 
to IL-6 concentrations in acute respiratory 
distress syndrome and sepsis and lower 
than those in patients with cytokine release 
in CAR-T cell therapy. Also noted were 
the disappointing results thus far of IL-6 
blockade in numerous randomized clinical 
trials, several of which have been halted  
due to futility. In the ACR database, the 
only one in which IL-6 inhibitors are 
tracked, patients with connective tissue 
diseases appeared to have increased risk 
of death from COVID-19 if treated with 
IL-6 inhibitors. However, this was based 
on a small number of patients, with a wide 
confidence interval.
Nonetheless, Calabrese echoed 
Woodcock in questioning the timing  
of IL-6 blockade administration as a 
potential key to the lack of efficacy, citing 
studies in which genetic polymorphisms in 
the IL-6R gene that reduce IL-6 signaling 
were shown to be salutary in COVID-19 
as well as in cardiovascular disease. For 
example, the Asp358Ala variant of the 
IL-6R receptor disrupts IL-6 signaling and 
is associated with reduced cardiovascular 
disease frequency in the general population 
and lower risk of both SARS-CoV-2 
infection and hospitalization for COVID-19 
(ref. 36). Calabrese concluded that  
timing may indeed be a key issue in the 
appropriate use of IL-6 inhibitors and  
that treatment with such agents at the 
onset of disease rather than later may have 
beneficial effects.
The final topic was treatment of  
COVID-19 with the JAK inhibitor 
baricitinib. Noting that the ACTT-2 trial of 
baricitinib and remdesivir versus remdesivir 
alone had a favorable but very modestly 
improved outcome for the combination 
therapy (shortening of clinical disease by 
only one day), Calabrese stressed that such 
limited efficacy must be weighed against 
the potential adverse consequences of 
baricitinib, including inhibition of numerous 
cytokines that may play an important role 
in antiviral responses (type I IFNs, IL-12, 
and so on), promotion of thromboembolism 
(already a critical problem in patients with 
COVID-19) and activation of endogenous 
viruses, including herpes and BK viruses. 
These potential negative effects must be 
considered carefully against the marginally 
improved outcome when baricitinib is 
given in combination with remdesevir, 
along with the antiviral properties that 
have been identified for baricitinib37. Other 
considerations regarding this agent include 
issues of the timing of administration and, 
critically, how its administration should be 
considered in view of the known salutary 
effects of dexamethasone for severe disease.
Finally, in addition to citing the utility 
of registries for providing insights and 
for hypothesis generation, Calabrese 
concluded that the current data support 
contextual roles for cytokines in disease 
and their inhibitors in treatment, and these 
are influenced by disease stage and the 
associated immunologic ‘endotype.’ Such 
considerations should be fundamental in 
designing new trials. Importantly, all three 
speakers agreed that the consensus at this 
time is that infection with SARS-CoV-2 
does not lead to flare-ups in patients with 
AIDs. Of note, Calabrese remarked that 
many patients had altered their treatment 
following the onset of the pandemic, 
complicating the assessment of the 
consequences of the virus for these patients.
Concluding remarks
It has become abundantly clear that 
cytokines play a commanding role in the 
pathogenesis of COVID-19. Cytokine 
expression is not only a prognostic 
biomarker for the disease outcome and 
severity of COVID-19, but SARS-CoV-
2-induced cytokine expression is also 
understood to be a potent agitator of the 
host immune system, leading to destructive 
autoinflammation, organ failure and death. 
As such, the second NIH/FDA symposium 
on Cytokines in COVID-19 was timely, 
showcasing cutting-edge research conducted 
by the immunology community to 
understand the cytokine-driven pathology 
of COVID-19. Harnessing knowledge of the 
virus as well as of autoimmune processes, 
the speakers highlighted emerging areas 
of research that may yield new therapeutic 
targets to reduce the clinical impact of the 
disease and minimize sequelae.
The virtual nature of the symposium 
permitted speakers and audiences from 
around the world to participate in real 
time, with over 800 viewers logging in 
on the day of the event and many more 
subsequently making use of the archived 
videos. Such worldwide interest illustrated 
the cutting-edge nature of the talks but also 
accentuated the need for rapid dissemination 
of COVID-19-related data to the scientific 
community. Nonetheless, it was also clear 
that many questions remain, including the 
expression patterns and timing of cytokines 
that are relevant to the disease course and 
how differences in genetics and environment 
may contribute. Furthermore, the many 
nuances to measuring cytokines, including 
methods for and timing of the collection, 
treatment, storage and assay of samples, 
may need to be addressed before specific 
cytokines can be used reproducibly as disease 
biomarkers to monitor and predict disease 
progression and recovery. SARS-CoV-2 
presents a set of unique challenges that 
require navigation through uncharted 
territories and collaboration on the part of 
the scientific community. We expect that 
increasing efforts to interrogate the role of 
cytokines in COVID-19 will provides us 
with new tools to map and understand the 
molecular landscape of this viral disease. ❐
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